
Life Sciences in Washington

Technology, Energy and Communications
November 21, 2006

**Dr. Lee Huntsman, Executive Director,
Life Science Discovery Fund.**

State Context

Global

- Connected
- Self concept
- Benchmarks
- Recognition

Innovative

- Consortia
- Companies
- Institutions
- Technology

Networked

- Non-hierarchical
- Modest gov't
- Comm'y Action
- Collaborative

Altruistic

- Non-profits
- Global health
- Philanthropy
- Relief

Entrepreneurial – high rate of company formation & closure

Trade dependent – 20% of jobs related to trade

Washington: 6M people; Strong in ag, aerospace, tech, retail

Biomedical Enterprises

Research

- 2 res univ's
- Top ca center
- Many institutes
- National lab

Companies

- Drugs on mkt
- Drug devel't
- Devices strong
- IT

Non-profits

- Gates Fndn
- Global Partners
- PATH
- Relief agencies

Providers

- Diversified
 - Insurance
 - Partnered
 - Regional reach
-

Biomedical Enterprises

Research

- 2 res univ's
- Top ca center
- Many institutes
- National lab

Companies

- Drugs on mkt
- Drug devel't
- Devices strong
- IT

Non-profits

- Gates Fndn
- Global Partners
- PATH
- Relief agencies

Providers

- Diversified
- Insurance
- Partnered
- Regional reach

Government Support

State:

LSDF; WTC; SIRT

R&D tax incentives

State-wide strategy

Regional:


Medical school for five states

Local:


Active EDCs and local enablers

UW External Grants and Contracts

\$996M



NIH Grants (about \$1B/year)




Companies and Institutions

WBBA Members


423 total

182 core




Research Institution Employment

About 12,000 total



Company employment: 30,000 estimate

Bioscience PhD Enrollment



Directions


- Institutional cooperation
 - Deep financial: UW with FHCRC, CHMC
 - Grants and students everywhere
 - Multi-disciplinary initiatives
 - Stem cell/Regenerative medicine
 - Imaging, Nano, Vaccines
 - D2H2
 - Leveraging
 - Shared facilities
 - International partnerships
-

Directions


- Evolving focus on health
 - Precision, predictive, preventative
 - Home
 - Global
 - Facilities expansion
 - Lake Union; Spokane
 - Amgen Helix campus
 - Gilead growth
 - Drug production capacity
 - Public/political support
-

Moving research to products

- zone of few resources
- changing landscape




Facilitating transfer of technologies



Health Care

Is there potential to:

- create counter forces
- get others to help fund
- improve care



Zones of Opportunity

- Early stage technologies/companies
 - Cost reducing medical technologies
 - Hybrid technologies
 - ❑ Drugs/imaging
 - ❑ Cells/implants
 - ❑ Bio-markers/point of care assays
-

Life Sciences Discovery Fund

Life Sciences

Health Related
Discovery, Products, Services

Ag - Biotech - Devices - Health Care

LSDF and the Life Sciences Sector

- Motivation = economic development
 - Metrics of success = \$, jobs
 - Need ROI within reasonable time
 - Research is a key engine
 - Needs some local fuel
 - Industry sector is too small
 - Attract or create more companies
 - Health Care delivery
 - Small efficiencies = serious ROI
-

Research

- Research is an industry
 - Imports high impact money
 - Provides skilled people
 - Creates IP
 - Washington research is strong
 - State support has been weak
 - LSDF is to research as tax breaks are to other industries
-

Life Sciences Fund & Authority

- Created by SB 5581 in 2005
 - to make competitive grants to research institutions and their partners
 - Governed by 11 Trustees
 - 7 appointed by the Governor and 4 by the legislature
 - Funded by bonus tobacco payments
 - starting in 2008; \$35M/yr
-

Board of Trustees

- Dr. Lura Powell, Chair
 - Dr. Rita Colwell
 - Dr. Jim Cook
 - Dr. Tony Hey
 - Governor Gary Locke
 - Dr. Bruce Montgomery
 - Cheryl Scott
 - Sen. Lisa Brown
 - Sen. Jerome Delvin
 - Rep. Jeff Morris
 - Rep. Skip Priest
-

Underway

- Trustees meet bimonthly
 - Operational funding from State
 - Ideas/perspective from sectors
 - Programmatic/operational planning
 - Expected timeline
 - RFP Spring '07
 - Review/award decisions Fall '07
 - Grant funds Spring '08
-

Core Strategy = Leverage

Enable initiatives that:

- Improve cost effectiveness
- Compete for external \$
- Attract investment

Not a source of:

- Operating support
 - Equity capital
-

LSDF

Accelerating the Promise of Life Sciences by:

- Enabling research institution success
- Speeding commercialization of research
- Stimulating cost effective care strategies

To the benefit of:

- Better health in Washington and beyond
 - Economic advances: jobs, funding
-

